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factors, pretransplant disease status and factors apart from
leukemia could affect the success of allo-SCT. It is still un-
certain that allo-SCT in CR1 has superior efﬁcacy especially
for those patients who have cytogenetically standard risk.
The optimization of supportive care in last 2 decades
decreased early transplant related mortality substantially. In
this intent-to-treat, single center, retrospective study we
analyzed 40 consecutive AML patients who underwent allo-
SCT between January 2011 and November 2013 at our center
to determine the role of allo-SCT in CR1 or beyond. Patients
were evaluated for overall survival (OS), disease free survival
(DFS), early (30-100 day) and late (101-365 day) transplant
related mortality (TRM). Survival was estimated using the
KaplaneMeier method, and the log-rank test was used to
compare survival curves among variables. Median age was
48 years (19-64 y). Among those patients who had cytoge-
netic data (28 patient, 70%), 12 (30%) were in high-risk
category. Median time from diagnosis to allo-HCT was 6.5
months (2-54 months). Median follow-up period for living
patients was 419 days (105-857). Status at tx: 24 patients
(60%) in CR1, 12 patients (30%) in CR2 and 4 patients (10%)
who received myeloablative (Bu16-CY120) (n¼32, 80%) or
reduced-intensity regimens (Flu150-Bu8)(n¼8, 20%). Donors
were matched related for 32 patients (80%), unrelated for 7
patients (17.5%) and haploidentical for 1 patient (2.5%). All
but 2 patients (95%) received PBSC. All patients received
primary antifungal prophylaxis. Overall, TRM at day 30 and
100 were 7.5% (n¼3) and 10% (n¼4), respectively. Late death
(>100 days) was observed in 7 patients (17.5%) and 3 of them
were related to allo-SCT. Grade 2-4 aGVHD was seen in 20
(50%) patients and chronic extensive GVHD in 8 patients
(20%). Of those 24 patients who underwent allo-HCT in CR1,
18 patients (75%) were still in remission without any sign of
disease. Nine of 16 patients (56.3%) who underwent allo-SCT
beyond CR1 lost due to relapsed leukemia. Survival analysis
revealed superior OS between patients in CR1 (median 901
days) and beyond CR1 (median 202 days) (log-rank, OS
p¼0.003)(Fig 1). For disease free survival we have seen the
same proﬁle (p¼0.007). In CR1 patients (n¼24) univariate
analysis revealed no impact of standard-risk cytogenetics,
high HCT-CI (2), high WBC at dx (>30k), sex (F to M), ABO
mismatch and double induction for CR achievement. The
only adverse factor for short OS in CR1 was past history of
invasive fungal infection pre allo-SCT (p¼0.038, 901d vs
553d). Allogeneic HCT in AML patients should be undertakenin CR1 with matched sibling donor. Pre-tx invasive fungal
infection was the only worst predictive factor for OS in CR1.382
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In the Germanmulticentre ALL studies, all patients (pts) with
induction failure or after relapse are candidates for allogeneic
SCT. We report here our single center data on 57 pts. Median
age was 28 years (18-57). ALL subtypes were: Ph+ ALL (n¼8),
B-lineage (pre B, B, pro B) (n¼36), T lineage (pre T, mature T,
thymic) (n¼13). Before conditioning, 12/57 pts had induction
failure, 31/57 pts were in CR2, 8/57 pts in 2. relapse, and 6/57
pts in CR3.Median duration of CR1 (n¼45)was 21months (2-
107), CR2 (n¼14) was 4 months (1-168). Pts with induction
failurehadat leastGMALL, Induction I+II followedby2 further
protocols. Induction chemotherapy of relapse varied and
consisted of the GMALL protocol, ALL relapse protocol, Ida-
FLAG, CLAEG, GIMEMA protocol, and local therapy of extra-
medullary leukemia. 27/37 pts transplanted in CR2 or CR3
reached CR after 1. chemotherapy, 7 after 2. chemotherapy,
and 3 after 3. chemotherapy. Conditioning regimen was
myeloablative (12Gy TBI + Cy/ VP16) in 49 pts, reduced in-
tensity conditioning (8Gy TBI or Flu+Bu+ATG) in 7 pts, and
Treosulfan in 1 pt. Donors were matched unrelated donors
(MUD) in 35 pts, HLA identical siblings in 21 pts, and a HLA-
compatible child in 1 pt. GvHD prophylaxis was mainly CSA/
MTX, since 2005 ATG was given in MUD additionally.
Results: 13/57 pts (23%) are alive in continuous CR (CCR).
The median follow-up after allo-SCT for surviving pts is
155 months (5-222). 26/57 pts died due to relapse, 18/57
pts due to treatment-related mortality (TRM), mainly
GvHD and/or infections. Probability of leukemia free sur-
vival (LFS) at 48 months is 25% for pts with induction
failure, 30% for pts in CR2, 12% for pts in second relapse,
and 33% for pts in CR3.
Conclusions: Adult ALL pts after 1. relapse can only be cured
by allo-SCT, but the relapse rate is high. The same is true for
ALL pts with induction failure/primary refractory. Perspec-
tive in the GMALL studies is to transplant pts with molecular
failure before hematologic relapse occurs. In patients with
induction failure, up to now, allo-SCT is the only chance of
cure. In B-lineage ALL, Blinatumomab may improve the re-
sults as bridging to allo-SCT.383
The Use of a Reduced-Intensity Conditioning (RIC)
Regimen in Patients Ages 2-30 Undergoing Allogeneic
Transplantation for Sickle Cell Disease
Suhrad Banugaria 1, Alfred P. Gillio 2, Jeanette Haugh 2,
Nancy Durning 2, Melanie Nycz 2, Barbara Adler-Brecher 2,
Jennifer Krajewski 2. 1 Pediatrics, New Jersey Medical School,
Rutgers University, Newark, NJ; 2 Institute for Pediatric Cancer
and Blood Disorders, Hackensack University Medical Center,
Hackensack, NJ
Table 1a
Baseline Characteristics
Patient Characteristic Bu-Cy Cy-Bu P Value
Total patients 18 22
Sex .424
Male 15 16
Female 3 6
Age
Median (range) 17 (1-50) 16 (1-48) .85
Mean 21.83 22.81 .899
<14 yr 7 7
14-45 yr 10 13
>45 yr 1 2
Underlying disease .415
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dividuals in the United States and causes considerable
morbidity and mortality. Hematopoietic stem cell trans-
plantation (HSCT) is the only cure for patients with SCD.
Multiple studies show matched sibling transplants after
myeloablative (MAB) conditioning have acceptable results,
but with potential long-term complications, like endocrine
and fertility issues. Only 14% of SCD patients will have
acceptable sibling donors, and results have been less
promising with higher rates of transplant related mortality
(TRM) using alternative donors after MAB conditioning.
Historically, only pediatric patients were considered can-
didates for HSCT, but a recent study demonstrated that
young adult SCD patients may be able to tolerate a RIC
HSCT with minimal complications. In an attempt to
minimize the risk of TRM while still maximizing the
available donors, this study examines the use of a RIC
regimen for either matched sibling or alternative donor
HSCT in SCD patients ages 2-30.
Methods: Patients were deemed eligible for matched sibling
HSCT if they had SCD, and for alternative donor HSCT if they
had SCDwith severe features with a 9-10/10 unrelated donor
or 5-6/6 UCB in the donor registry. The conditioning regimen
consisted of Alemtuzumab, Fludarabine, and Melphalan.
Post-HCST, donor chimerism and hemoglobin S (HbS) per-
centages were followed closely, and there was strict moni-
toring for post-HSCT complications, including graft rejection,
graft vs. host disease (GVHD), infectious complications, and
other post-HSCT issues.
Results: 11 patients (8 related donors, 3 unrelated donors)
with median age of 8.1 years (range: 2.3-23 years) were
enrolled. For related HSCT, the probabilities of primary
neutrophil & platelet engraftment, grade II-IV acute GVHD,
chronic GVHD, and graft rejectionwere 100%, 27%, 12.5%, and
0%, respectively. Donor chimerisms ranged from 96-100%
with HbS% between 0-43%, with median follow-up of 19
months (range: 3-24months). Probability of 1-yr DFS and OS
were 100% & 100%. For alternative donor HSCT, the proba-
bilities of primary neutrophil & platelet engraftment, grade
II-IV GVHD, chronic GVHD, and graft rejection were 100%,
33%, 33%, and 33%, respectively. Donor chimerisms ranged
from 0-100%with HbS% between 0-18%, with median follow-
up of 8 months (range: 2-25 months). Probability of 1-yr DFS
and OS were 33% & 66%.
Conclusions: Our results show that this RIC regimen fol-
lowed by matched sibling HSCT is well tolerated, but the
results were discouraging for alternative donor HSCT.
Because of this, we are currently developing a protocol using
post-transplant cyclophosphamide in alternative donor
HSCT for SCD.AML 14 12
ALL 3 4
CML 1 3
MDS 0 2
Primary myeloﬁbrosis 0 1
Stage of disease .984
Early 3 4
Intermediate 8 10
Late 7 8
Pre-transplant remission status .482
CR 11 11
Not in CR 7 11
Performance status (ECOG) .314
0 4 3
1 9 16
HSCT comorbidity index .341
0 14 15
1 1 5
2 2 2
3 1 0384
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Most adult ALL protocols include consolidation chemotherapy,
yet whether the consolidation is beneﬁcial in patients under-
going alloHCT in ﬁrst complete remission (CR1) remains un-
certain. We therefore studied the impact of consolidation
chemotherapy on transplant outcomes of 75 consecutive ALLpatientswho received alloHCT in CR1 between 2004 and 2013.
Patientswho received at least 1 cycle of consolidation (n¼51; 1
cycle, n¼25;2 cycles, n¼26)were compared to thosewithout
consolidation (n¼24) chemotherapy prior to alloHCT. The
median age of entire cohort was 42 years (range, 19-67) and
59% were males. Half had Ph+ ALL and 16% had CNS leukemia.
Patients received median of 2 cycles of induction chemo-
therapy (range, 1-5), and the median time from diagnosis to
CR1 was 1.6 months (range, 1.1-2.9). Among 54 patients
evaluable for minimal residual disease (MRD), 42 were MRD
negative prior to alloHCT. Most patients received myeloa-
blative conditioning (67%) and umbilical cord blood (UCB, 63%)
alloHCT. Patients in 1 consolidation group were more often
transplanted after 2008 (75% vs. 31%, p<0.01) as compared to
no consolidation group, however other patient, disease and
transplant characteristics were similar in both groups. At a
median follow up of 4 years (range,1-8), patients treated with
1 cycles of consolidation versus no consolidation had similar
1-year non-relapse mortality (24% vs. 29%, p¼0.23), 2-year
leukemia relapse (23% vs. 25%, p¼0.44), leukemia-free survival
(48%vs. 36%,p¼0.18) andoverall survival (61%vs. 45%,p¼0.15),
respectively. Cumulative incidence of relapse was lower in
MRD negative patients (17% vs 50% MRD+, p¼0.03) and UCB
recipients (15%vs 37% related donor, p¼0.02). Our data suggest
that ALL patients with available donor undergoing alloHCT in
CR1may not beneﬁt from further pre-transplant consolidation
chemotherapy.385
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